Morgan Stanley lifted its target price and gave an overweight rating for Arrowhead Pharmaceuticals, while Norges Bank acquired a new stake in the company's shares.
2 reports, 1 independent
Updated Aug 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley lifted its target price and gave an overweight rating for Arrowhead Pharmaceuticals, while Norges Bank acquired a new stake in the company's shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Norges Bank
central bank of Norway
Related events
- Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.
- Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
- Morgan Stanley lifted its price target on FactSet Research Systems Inc., while Royal Bank of Canada restated a sector perform rating.
- Morgan Stanley set a $38.00 target price for Kinder Morgan on August 16, 2026.
- Multiple financial firms (Barclays, UBS, Morgan Stanley, Jefferies) issued rating and price target updates for Equity Lifestyle Properties.
Coverage
Newest first; wire copies grouped- tickerreport.comInceptionr LLC Purchases New Position in Arrowhead Pharmaceuticals, Inc. $ARWR